Last reviewed · How we verify
Lyophilized albiglutide DCC pen injector
Lyophilized albiglutide DCC pen injector is a GLP-1 receptor agonist Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Type 2 diabetes.
Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to lower blood glucose levels.
Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to lower blood glucose levels. Used for Type 2 diabetes.
At a glance
| Generic name | Lyophilized albiglutide DCC pen injector |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By activating the GLP-1 receptor, albiglutide increases insulin secretion in response to high blood glucose levels, decreases glucagon secretion, and slows gastric emptying, leading to improved glycemic control.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Injection site reactions
Key clinical trials
- Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus (PHASE3)
- A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus (PHASE3)
- Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lyophilized albiglutide DCC pen injector CI brief — competitive landscape report
- Lyophilized albiglutide DCC pen injector updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Lyophilized albiglutide DCC pen injector
What is Lyophilized albiglutide DCC pen injector?
How does Lyophilized albiglutide DCC pen injector work?
What is Lyophilized albiglutide DCC pen injector used for?
Who makes Lyophilized albiglutide DCC pen injector?
What drug class is Lyophilized albiglutide DCC pen injector in?
What development phase is Lyophilized albiglutide DCC pen injector in?
What are the side effects of Lyophilized albiglutide DCC pen injector?
What does Lyophilized albiglutide DCC pen injector target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Compare: Lyophilized albiglutide DCC pen injector vs similar drugs
- Pricing: Lyophilized albiglutide DCC pen injector cost, discount & access